33 results about "Corneal nerve" patented technology

The invention provides methods and compositions for minimizing, preventing, or treating damage to corneal nerves by administering to a subject with such damage or at risk of exposure to such damage a composition which blocks an activity of an IL-1 cytokine and/or an IL-17 cytokine.

The present invention discloses a fungal keratitis image recognition method based on RX anomaly detection and texture analysis. The method comprises a step of obtaining a normal corneal nerve image and a mycelium image which comprises mycelium only as a training sample, a step of obtaining the fundus image of a fungal keratitis patient as a test sample, a step of carrying out preprocessing, feature extraction and feature integration on the normal corneal nerve image in the training sample to obtain a nerve feature after training sample integration, a step of carrying out preprocessing, feature extraction and feature integration on the mycelium image which comprises the mycelium only in the training sample to obtain a mycelium feature after the training sample integration, a step of carrying out preprocessing, feature extraction and feature integration on the image in the test sample to obtain the nerve feature after test sample integration and the mycelium feature after the test sample integration, and a step of recognizing the nerve and mycelium in the test sample.

The present invention discloses the application of nerve polypeptide PACAP38 in the preparation of eye disease curing, injury repair or reproduction drugs. Compared with symptomatic treatment artificial tear aiming at corneal epithelium repair or tear streaming delay and the like at the existing market, by researching the function of the nerve polypeptide PACAP38 in corneal nerve repair and reproduction after rabbit eximer laser in-situ keratomileusis and the function of the nerve polypeptide PACAP38 for rabbit trigeminal ganglion cell proliferation and differentiation, the nerve polypeptide PACAP38 with certain concentration has an obvious growth promotion function for corneal nerve after an LASIK operation and rabbit trigeminal ganglion cells cultured outside a body; and thus, the present invention provides a new plot for xerophthalmia curing, cutting operations of cataract and eximer laser photorefractive keratectomy, and corneal nerve injures caused by other eye and systematic diseases.

The present invention is directed to a software algorithm that measures the number of corneal nerve fibers in images captured by microscopy including images from patients obtained by in vivo corneal confocal microscopy, a noninvasive technique. The present invention solves a complicated segmentation problem, by exploiting the piece wise linear nature of the nerve fibers—i.e., the nerves are made up of a lot of straight line segments. The image is split into sub-regions, where each sub-region contains nerves mostly running in the same, straight direction. Having the nerves all in straight-lines within a single 2d image region dramatically simplifies the segmentation problem. The image intensities are summed in the direction of the nerves to reduce the 2d representation to a 1d signal having pronounced peaks where the nerves are located.

The present invention relates to a biological deriving amniotic membrane, composite biological deriving amniotic membrane and method for making same, as a material used for repair engineering of skins, corneas and nervous tissues and clinical application, especially for the biological deriving amniotic membrane treated through a de-cell process and the composite biological deriving amniotic membrane formed by recombination with collagen sponges. The biological deriving amniotic membrane and the composite biological deriving amniotic membrane prepared by adopting the process in accordance with the present invention keep the complete spatial structure of amniotic membrane and entirely remove cells therein, with a very low antigen character. The biological deriving amniotic membrane and the composite biological deriving amniotic membrane in accordance with the present invention are used for defending tissue adhesions in surgical operations, biological dressings, eye surface transplantation and disease treating in tissue engineering skins, corneas, nerves and the like; can guard against tissue adhesions, promote cell adhesions, shorten the time for skin healing, alleviate patient aches, rebuild normal structure of eye surfaces, without leading to immunoreactions and with high security.

The embodiment of the invention provides an eyeball cornea nerve segmentation method and device based on a convolutional neural network model. The method comprises the following steps: acquiring an eyeball cornea layer image of an in-vivo confocal microscope; inputting the eyeball cornea layer image of the in-vivo confocal microscope into a preset convolutional neural network model to obtain an eyeball cornea nerve segmentation result corresponding to the eyeball cornea layer image of the in-vivo confocal microscope and a parameter result corresponding to the eyeball cornea nerve segmentation result, wherein the parameter result comprises a length parameter, a width parameter and a density parameter of corneal nerves of eyeballs. According to the embodiment of the invention, the cutting and parameter calculation of the corneal nerve fiber can be completed at the same time, so that the automatic cutting and parameter evaluation of the corneal nerve can be realized quickly and efficiently, and the auxiliary diagnosis process of ocular surface diseases such as dry eyes can be realized.

The invention discloses a U-shaped network and a segmentation method of nerve fibers in a cornea image, the U-shaped network comprises four layers of encoders and decoders, and the encoders and the decoders are symmetrically connected in a cross-layer manner; a multi-scale separation and fusion module is added after the upsampling operation of the decoder part; according to the U-shaped network, the parameter quantity is reduced, the receptive field is increased, and the segmentation performance is improved; the segmentation method adopts the trained U-shaped network, and the loss function adopts the combination of the fiber length difference between the prediction graph and the gold standard and the Dice loss to jointly constrain the U-shaped network. According to the method, fine cornealnerve fibers can be accurately segmented, and the segmentation precision of the corneal nerve fibers is improved.

The topical administration of a combination of nerve growth factor (NGF) and docosahexaenoic acid (DHA) has been discovered to synergistically increase the effects of NGF in re-innervating the cornea. This enhancement in corneal nerve re-growth will yield a faster anatomical and functional recovery after PRK or LASIK surgeries. Using rabbits, the application of NGF and DHA resulted in increased corneal nerve surface area, increased epithelial proliferation, and decreased rose bengal staining as compared with NGF, DHA, or vehicle control individually. The topical application of NGF plus DHA in accelerating the re-innervation after PRK or LASIK, will help avoid or alleviate the symptoms of dry eye or other neurotrophic keratopathies due to corneal injuries. The topical application can be by using a corneal shield or lens. This treatment will also be useful in other corneal abnormalities including those caused by chemical burn, congenital corneal neuropathy, or acquired corneal neuropathy.

The invention relates to a light-sheet microscopy for corneal nerve imaging and belongs to the technical field of corneal nerve imaging. The light-sheet microscopy comprises a control device, an illumination light path and an image acquisition light path. The illumination light path injects light into the cornea of the eye, forming a dynamic light sheet at an angle of alpha with the horizontal plane at the position of the cornea of the eye; an image signal is transmitted into the image acquisition light path at an angle of beta with the horizontal plane, and the image acquisition light path sends the image signal into the control device for imaging, wherein the angle between the angle of alpha and the angle of beta is 90 degrees, and the angle of alpha is unequal to 90 degrees. The dynamiclight-sheet microscopy is used to acquire a corneal nerve image, accelerate an imaging speed, reduce the shooting time, and avoid the injury to eyes caused by illumination light directly shining thefundus.

The invention relates to an annular microneedle for ophthalmology, and belongs to the technical field of biology. The invention provides a microneedle. The microneedle comprises a needle body and a substrate, the needle body is fixed on the base; the base is annular, and the shape and the size of the base are matched with those of the sclera edge; the microneedle acts on the sclera margins of human canthus, eye diseases are treated by rapidly penetrating into the corneal stroma layer and dissolving and releasing contained drugs, the bioavailability of ocular surface drugs is remarkably improved, meanwhile, compared with a traditional non-invasive multi-array square microneedle, the microneedle is small in size, does not affect the light transmission of the center of the cornea, and can be applied to the field of ophthalmology. The stimulation to corneal nerves in a central area is smaller, the problems that a traditional non-invasive multi-array square microneedle can cause reduction of corneal translucency and is prone to causing corneal pain can be effectively solved, and the biological safety of eye microneedle administration and patient compliance are improved.

The invention provides application of Sirt1 in repairing corneal nerve injury. It is discovered herein that Sirt1 may promote the repairing of corneal nerve injury and may also promote the preparing of corneal epithelial injury as well as the axonal growth of trigeminal ganglion cells; the Sirt1 may be used to culture trigeminal ganglion cells, repair persistent corneal epithelial defect, repair diabetic corneal nerve injury and repair nervous keratitis. Moreover, corneal nerve injury can be more effectively repaired by the joint use of silencing signal regulator 1 and miR-182-5p agonist.

The invention discloses a recombinant human collagen, a coding gene and an application of the recombinant human collagen in preparation of a biodegradable collagen-based corneal substitute, and the recombinant human collagen and the coding gene are obtained by treating the recombinant human collagen and a high-molecular polymer in a water phase in a composite cross-linking manner and curing and molding in a mold, or after the recombinant human collagen and the high-molecular polymer are subjected to electrostatic spinning to form a nanofiber membrane, the nanofiber membrane is further subjected to composite crosslinking and drying to obtain the three-dimensional corneal scaffold, and platelet-rich plasma is added for use after rehydration swelling in clinical application. The cornea substitute is free of virus hidden danger, free of immunogenicity, controllable in degradability and good in refraction and mechanical strength, and has a remarkable induction effect on regeneration of corneal epithelial cells, corneal bodies and corneal nerves after being added with platelet-rich plasma (APRP).

A multichannel stimulation system for regenerating damaged corneal nerves, includes: a multichannel unit including a first channel formed of a conductive material and attached between an area above a left eye and a left eyebrow to transfer a stimulation signal, and a second channel formed of a conductive material and attached between an area above a right eye and a right eyebrow to transfer the stimulation signal; and a stimulation signal module for providing the first channel and the second channel with an electric pulse signal as the stimulation signal, wherein the multichannel unit includes a contactor formed between the first channel and the second channel in one piece to electrically contact with the stimulation signal module.

The invention relates to the field of biological medicine, in particular to application of a compound LM22B-10 in preparation of a medicine for repairing corneal epithelium and nerve trauma. The invention discloses application of the compound LM22B-10 in preparation of a medicine for treating corneal epithelium and nerve injury, and belongs to the field of biological medicine. Pharmacodynamic tests prove that after normal mice with corneal epithelium injury and type I diabetic mice are taken as experimental subjects and LM22B-10 eye drop administration is carried out, the length and density of corneal nerve fibers are remarkably increased, the corneal epithelium recovery speed is obviously increased, and the corneal sensitivity is basically recovered to be normal. The compound has a relatively good treatment effect on corneal nerve injury caused by keratitis, xerophthalmia, full femtosecond laser myopia correction, excimer laser surgery, diabetes and the like, and eye symptoms of patients can be relieved; and the drug toxicity is small, the stability is good, and important development and application prospects are realized.